drotrecogin alfa


Also found in: Dictionary, Thesaurus, Wikipedia.

drotrecogin alfa

a thrombolytic agent used to treat severe sepsis associated with organ dysfunction.
References in periodicals archive ?
Indeed, while some components of the sepsis bundles require further study, some such as drotrecogin alfa may soon be obsolete given the negative results of a recent landmark study (23).
In vitro data also indicate that drotrecogin alfa (activated) may exert anti-inflammatory effects through several mechanisms.
The FDA had previously approved a treatment-use protocol to allow access to drotrecogin alfa (activated) for patients who meet the clinical criteria of sepsis with associated acute organ dysfunction.
Drotrecogin alfa was started at a dose of 24 [micro]g/kg/h and was continued for two days, at which point a worsening coagulopathy (INR to 3.
Drotrecogin alfa (Xigris) is indicated only for adult patients with severe sepsis who are at high risk of death.
Outcomes assessed were presence of contraindications to treatment with drotrecogin alfa (activated), an admission APACHE II score of 25 or greater and dysfunction of two or more organs.
That's the key message from a large study of patients who received drotrecogin alfa (Xigris) at 139 hospitals in the United States between November 2001 and June 2003, Frank Ernst, Pharm.
Median survival was 1,113 days in a group of patients treated with the drug, known as drotrecogin alfa, compared with 846 days in placebo-treated patients, said Dr.
PHILADELPHIA -- Critical care physicians are now faced with the difficult decision of which patients with severe sepsis are appropriate candidates for drotrecogin alfa.
The drug, drotrecogin alfa (activated) (APC) is a genetically engineered version of a naturally occurring human protein that interferes with some of the body's harmful responses to severe infection, including the formation of blood clots that can lead to organ failure and death.
The members of the Food and Drug Administration's Anti-Infective Drugs Advisory Committee who voted against approval called for another study to be conducted to confirm the findings of a significant reduction in mortality with the therapy drotrecogin alfa (activated), in a multicenter study of patients with severe sepsis.
Jesse Hall, MD, FCCP, of the University of Chicago Pritzker School of Medicine, reviewed drotrecogin alfa (activated), a drug recently-approved by the FDA that reduces mortality from severe sepsis.